Staidson Beijing Biopharma - Asset Resilience Ratio

Latest as of September 2022: 7.93%

Staidson Beijing Biopharma (300204) has an Asset Resilience Ratio of 7.93% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Staidson Beijing Biopharma balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥130.40 Million

≈ $19.08 Million USD Cash + Short-term Investments

Total Assets

CN¥1.64 Billion

≈ $240.56 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2021)

This chart shows how Staidson Beijing Biopharma's Asset Resilience Ratio has changed over time. See 300204 net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Staidson Beijing Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Staidson Beijing Biopharma market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥130.40 Million	7.93%
Total Liquid Assets	CN¥130.40 Million	7.93%

Asset Resilience Insights

Limited Liquidity: Staidson Beijing Biopharma maintains only 7.93% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Staidson Beijing Biopharma Industry Peers by Asset Resilience Ratio

Compare Staidson Beijing Biopharma's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for Staidson Beijing Biopharma (2016–2021)

The table below shows the annual Asset Resilience Ratio data for Staidson Beijing Biopharma.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2021-12-31	20.88%	CN¥381.46 Million ≈ $55.82 Million	CN¥1.83 Billion ≈ $267.35 Million	-3.97pp
2020-12-31	24.85%	CN¥461.24 Million ≈ $67.49 Million	CN¥1.86 Billion ≈ $271.62 Million	+10.08pp
2019-12-31	14.77%	CN¥275.00 Million ≈ $40.24 Million	CN¥1.86 Billion ≈ $272.53 Million	-2.58pp
2018-12-31	17.35%	CN¥480.85 Million ≈ $70.36 Million	CN¥2.77 Billion ≈ $405.65 Million	+6.80pp
2017-12-31	10.54%	CN¥277.10 Million ≈ $40.55 Million	CN¥2.63 Billion ≈ $384.64 Million	-15.32pp
2016-12-31	25.86%	CN¥607.86 Million ≈ $88.95 Million	CN¥2.35 Billion ≈ $343.97 Million	--

pp = percentage points

About Staidson Beijing Biopharma

SHE:300204 China Biotechnology

Market Cap

$1.93 Billion

CN¥13.20 Billion CNY

Market Cap Rank

#6408 Global

#1438 in China

Share Price

CN¥27.63

Change (1 day)

-0.79%

52-Week Range

CN¥10.31 - CN¥61.00

All Time High

CN¥61.00